William Reece, MD
Investigators are attempting to advance the late-stage non–small cell lung cancer (NSCLC) treatment paradigm by combining an emerging antimitotic modality with standard-of-care (SOC) therapies in the phase III LUNAR trial (NCT02973789).
The primary end point will be overall survival (OS) of patients treated with TTFields and either ICIs or docetaxel versus docetaxel or ICIs alone, measured by superiority analysis. Secondary end points include various other OS measures, progression-free survival (PFS), and overall radiological response rate.
Figure. TTFields With SOC Therapies in Late-Stage NSCLC: Phase III Lunar Trial
... to read the full story